Alan J Garber

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. doi request reprint The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations
    Alan J Garber
    Department of Medicine, Biochemistry, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Endocr Pract 19:100-6. 2013
  2. doi request reprint Methods to enhance delivery of prandial insulin and basal-prandial insulin
    A J Garber
    Department of Medicine, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 15:11-7. 2013
  3. pmc Incretin therapy--present and future
    Alan J Garber
    Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, One Baylor Plaza BCM620, Houston, Texas 77030, USA
    Rev Diabet Stud 8:307-22. 2011
  4. ncbi request reprint Update: vildagliptin for the treatment of Type 2 diabetes
    Alan J Garber
    Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, 1709 Dryden, Suite 1000, Houston, TX 77030, USA
    Expert Opin Investig Drugs 17:105-13. 2008
  5. ncbi request reprint Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting
    Alan J Garber
    Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Ste 1000, Houston, TX 77030, USA
    Am J Manag Care 16:S187-94. 2010
  6. doi request reprint Hypertension and lipid management in prediabetic states
    Alan J Garber
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 13:270-4. 2011
  7. ncbi request reprint Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus
    Alan J Garber
    Department ofMedicine, Biochemistry, and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 3411, USA
    J Am Osteopath Assoc 111:S20-30. 2011
  8. doi request reprint Novel GLP-1 receptor agonists for diabetes
    Alan J Garber
    Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, One Baylor Plaza BCM620, Houston, TX 77030, USA
    Expert Opin Investig Drugs 21:45-57. 2012
  9. ncbi request reprint Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center
    John A Goss
    Baylor College of Medicine, Michael E DeBakey Department of Surgery, Houston, TX 77030, USA
    Transplantation 77:462-6. 2004
  10. ncbi request reprint Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
    Alan J Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 88:3598-604. 2003

Collaborators

Detail Information

Publications35

  1. doi request reprint The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations
    Alan J Garber
    Department of Medicine, Biochemistry, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Endocr Pract 19:100-6. 2013
    ..To review available data on the efficacy and safety of bromocriptine-QR (BQR) and to consider its role in the management of Type 2 diabetes mellitus (T2DM)...
  2. doi request reprint Methods to enhance delivery of prandial insulin and basal-prandial insulin
    A J Garber
    Department of Medicine, Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 15:11-7. 2013
    ....
  3. pmc Incretin therapy--present and future
    Alan J Garber
    Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, One Baylor Plaza BCM620, Houston, Texas 77030, USA
    Rev Diabet Stud 8:307-22. 2011
    ..Clearly, all of these properties are desirable for patients with prediabetes...
  4. ncbi request reprint Update: vildagliptin for the treatment of Type 2 diabetes
    Alan J Garber
    Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology, Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, 1709 Dryden, Suite 1000, Houston, TX 77030, USA
    Expert Opin Investig Drugs 17:105-13. 2008
    ..Across studies, vildagliptin was effective in reducing HbA(1c), had a low risk of hypoglycemia and was weight-neutral and well tolerated...
  5. ncbi request reprint Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting
    Alan J Garber
    Division of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine, Ste 1000, Houston, TX 77030, USA
    Am J Manag Care 16:S187-94. 2010
    ..The AACE/ACE guidelines clearly state that these agents should not be limited to third- or fourth-line therapy...
  6. doi request reprint Hypertension and lipid management in prediabetic states
    Alan J Garber
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Hypertens (Greenwich) 13:270-4. 2011
    ..Multiple antihypertensive agents are likely necessary for normotension. Aggressive statin usage is the first-line lipid therapy and concomitant fibrate and nicotinic acid usage should be reserved for failures in primary prevention...
  7. ncbi request reprint Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus
    Alan J Garber
    Department ofMedicine, Biochemistry, and Molecular Biology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030 3411, USA
    J Am Osteopath Assoc 111:S20-30. 2011
    ..The author reviews the safety and efficacy of currently approved incretin-based agents, as well as the role of these medications in treatment paradigms for patients with T2DM. He also discusses investigational incretin-based agents...
  8. doi request reprint Novel GLP-1 receptor agonists for diabetes
    Alan J Garber
    Baylor College of Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, One Baylor Plaza BCM620, Houston, TX 77030, USA
    Expert Opin Investig Drugs 21:45-57. 2012
    ..This review considers the mechanism of action of GLP-1 receptor agonists and considers the various agents in this class...
  9. ncbi request reprint Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center
    John A Goss
    Baylor College of Medicine, Michael E DeBakey Department of Surgery, Houston, TX 77030, USA
    Transplantation 77:462-6. 2004
    ..The PIT Food and Drug Administration (FDA) regulations, pancreatic islet isolation (PII) techniques, and clinical PIT protocols are challenging and make PIT program development daunting...
  10. ncbi request reprint Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes
    Alan J Garber
    Baylor College of Medicine and The Methodist Hospital, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 88:3598-604. 2003
    ....
  11. ncbi request reprint Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials
    Alan J Garber
    Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas, USA
    J Am Geriatr Soc 55:1735-40. 2007
    ..To compare the safety and efficacy of insulin detemir with that of neutral protamine Hagedorn (NPH) insulin in older (aged >/=65) and younger (aged 18-64) persons with type 2 diabetes mellitus (DM)...
  12. ncbi request reprint Diabetic dyslipidemia and the heart
    Abu R Vasudevan
    Center for Cadiovascular Disease Prevention, Lipoprotein and Atherosclerosis Research Section, Baylor College of Medicine, Houston, TX 77030, USA
    Heart Fail Clin 2:37-52. 2006
  13. ncbi request reprint Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study
    Alan J Garber
    Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030, USA
    Clin Ther 24:1401-13. 2002
    ....
  14. ncbi request reprint Current standards of care for inpatient glycemic management and metabolic control: is it time for definite standards and targets?
    Alan J Garber
    Baylor College of Medicine, Houston, Texas, USA
    Endocr Pract 10:10-2. 2004
    ..To review the available literature on the presence of diabetes in the inpatient population and its effect on outcomes...
  15. ncbi request reprint Role of insulin signaling in maintaining energy homeostasis
    Morali D Sharma
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
    Endocr Pract 14:373-80. 2008
    ..To examine the role that insulin signaling plays in modulating metabolic functions involving both peripheral and hypothalamic systems...
  16. ncbi request reprint Benefits of combination therapy of insulin and oral hypoglycemic agents
    Alan J Garber
    Baylor College of Medicine, Houston, Tex 77030, USA
    Arch Intern Med 163:1781-2. 2003
  17. ncbi request reprint Premixed insulin analogues for the treatment of diabetes mellitus
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
    Drugs 66:31-49. 2006
    ..In addition, given the convenience of mealtime dose administration, compliance with insulin therapy may increase with premixed insulin analogues...
  18. ncbi request reprint Point: Inpatient glucose management: the emperor finally has clothes
    Michael Bryer-Ash
    Gonda Diabetes Center, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at UCLA, 900 Veteran Ave, Suite 24 130, Los Angeles, CA 90095, USA
    Diabetes Care 28:973-5. 2005
  19. ncbi request reprint Premixed insulin treatment for type 2 diabetes: analogue or human?
    Alan J Garber
    Baylor College of Medicine, Faculty Center, Houston, TX 77030, USA
    Diabetes Obes Metab 9:630-9. 2007
    ..Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes...
  20. ncbi request reprint Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management
    Alan J Garber
    Department of Medicine, Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Diabetes Obes Metab 7:666-74. 2005
    ..In summary, the development of new insulin and other hormone preparations by the manipulation of native peptide structure has recently improved our antidiabetic armamentarium, and further research will continue this fruitful approach...
  21. doi request reprint Postprandial dysmetabolism and the heart
    Alan J Garber
    Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, 1709 Dryden Road, Houston, TX 77030, USA
    Heart Fail Clin 8:563-73. 2012
    ..Pharmacotherapies that target postprandial hyperglycemia and/or postprandial dyslipidemia are likely to improve endothelial function, which may have positive implications for cardiovascular outcomes...
  22. doi request reprint Current issues in GLP-1 receptor agonist therapy for type 2 diabetes
    Zachary T Bloomgarden
    Department of Medicine, Division of Endocrinology, Diabetes and Bone Disease, Mount Sinai School of Medicine, New York, New York, USA
    Endocr Pract 18:6-26; quiz 27-8. 2012
    ..The following review includes expert consideration of these topics with emphasis on recent, relevant reports to illustrate current perspectives...
  23. doi request reprint Building a solid foundation in diabetes: the nuts and bolts of insulin therapy
    Alan J Garber
    Departments of Medicine, Biochemistry and Molecular Biology, Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas
    Am J Med 125:S1-2. 2012
    ..amjmed.com). Click on the “Building a Solid Foundation in Diabetes: The Nuts and Bolts of Insulin Therapy” link in the “CME Multimedia Activities” section, found on the right side of the Journal homepage...
  24. ncbi request reprint What is the best treatment for prediabetes?
    Morali D Sharma
    Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, 1709 Dryden, Suite 1000, Houston, TX 77030, USA
    Curr Diab Rep 9:335-41. 2009
    ..For high-risk patients and those who progress despite intensive lifestyle modification, thiazolidinediones are also recommended. The goals for cardiovascular risk factor control are similar to those for patients with diabetes...
  25. ncbi request reprint An overview of incretin clinical trials
    Alan J Garber
    Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA
    J Fam Pract 57:S10-8. 2008
    ..The article also discusses some of the important clinical differences between GLP-1 receptor agonists and DPP-4 inhibitors...
  26. ncbi request reprint Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. Introduction
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, 6550 Fannin, Suite 1045, Houston, Texas 77030, USA
    Am J Med 118:1S-2S. 2005
  27. doi request reprint Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Alan J Garber
    Baylor College of Medicine, Houston, TX, USA
    Lancet 379:1498-507. 2012
    ..Insulin degludec is a new, ultra-longacting basal insulin. We aimed to assess efficacy and safety of insulin degludec compared with insulin glargine in patients with type 2 diabetes mellitus...
  28. ncbi request reprint Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center
    John A Goss
    Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
    Transplantation 74:1761-6. 2002
    ....
  29. ncbi request reprint The metabolic syndrome
    Alan J Garber
    Department of Medicine, Baylor College of Medicine, 6550 Fannin Street, Suite 1045, Houston, TX 77030, USA
    Med Clin North Am 88:837-46, ix. 2004
    ..A combination of chemoprevention and lifestyle modification may prevent many if not most cases of diabetes if treatment is instituted early...
  30. ncbi request reprint Cardiovascular complications of diabetes: prevention and management
    Alan J Garber
    Baylor College of Medicine, Methodist Hospital Houston, Texas, USA
    Clin Cornerstone 5:22-37. 2003
    ..For the most part, such management has been proven to reduce CV events in patients with diabetes, particularly type 2 diabetes...
  31. ncbi request reprint Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
    Emanuele Bosi
    Diabetes and Endocrinology Unit, Department of General Medicine, San Raffaele Scientific Institute, Vita Salute San Raffaele University, Milan, Italy
    Diabetes Care 30:890-5. 2007
    ..We sought to evaluate the efficacy and safety of vildagliptin, a new dipeptidyl peptidase-4 inhibitor, added to metformin during 24 weeks of treatment in patients with type 2 diabetes...
  32. ncbi request reprint Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes
    Alan J Garber
    Clin Ther 27:S39-41. 2005
  33. ncbi request reprint American College of Endocrinology position statement on inpatient diabetes and metabolic control
    Alan J Garber
    Endocr Pract 10:77-82. 2004
  34. ncbi request reprint American College of Endocrinology position statement on inpatient diabetes and metabolic control
    Alan J Garber
    Endocr Pract 10:4-9. 2004
  35. ncbi request reprint Reducing the risk of stroke through appropriate targets and treatments
    Michael H Davidson
    Prev Cardiol 10:215-21. 2007
    ....